基于血小板途径的抗血栓机制的研究

doi:10.3969/j.issn.2095-1396.2017.05.006

摘要/Abstract

摘要：

血液栓塞是心血管疾病发生的重要病理过程。血栓形成离不开血小板的参与，血小板在止血和动脉血栓形成中扮演重要角色。常见的血小板活化诱导途径有二磷酸腺苷途径、花生四烯酸途径、凝血酶途径、胶原途径和血小板活化因子途径。该文针对这5 种血小板活化机制、活化途径治疗药物以及新型靶点的抗血小板药物进行综述，为血液栓塞的研究和治疗提供一定参考。

关键词: 血液栓塞, 血小板途径, 血小板信号转导

Abstract:

Blood embolism is an important pathological process of cardiovascular disease. Thrombosis is closely related to platelet activation，and platelets play an important role in hemostasis and arterial thrombosis. The common platelet activation pathways to induce platelet aggregation include adenosine diphosphate pathway，peanut tetralic acid pathway，thrombin pathway，collagen pathway and platelet activation factor pathway. This article reviews the platelet activation mechanisms，activation pathway therapy drugs and new target antiplatelet drugs to provide some reference for the study and treatment of blood embolism.

Key words: blood embolism, platelet pathway, platelet signal transduction

中图分类号:

R964

引用本文

王保磊，王佳，郭春燕. 基于血小板途径的抗血栓机制的研究[J]. 神经药理学报, DOI: 10.3969/j.issn.2095-1396.2017.05.006.

WANG Bao-lei，WANG Jia，GUO Chun-yan. Study on Antithrombotic Mechanism Based on Platelet Pathway[J]. Acta Neuropharmacologica, DOI: 10.3969/j.issn.2095-1396.2017.05.006.

使用本文

0
/ 推荐

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://actanp.hebeinu.edu.cn/CN/10.3969/j.issn.2095-1396.2017.05.006

http://actanp.hebeinu.edu.cn/CN/Y2017/V7/I5/34

参考文献

[1] 贾俊. 红花注射抗血栓药效物质基础初步研究[D]. 太原: 山西大学, 2010.

[2] Martine Gilard, Paul Barragan, Arif A L Noryani. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial [J].J Am coll cardiol, 2015, 65(8):777-786.

[3] 周铭. 血小板聚集功能的检测——光谱学及软 X 线成像研究[D].合肥：安徽医科大学, 2016.

[4] 王晓锋, 陈乃宏, 王文. 抗血小板聚集药物的机制研究进展[J]. 中国康复理论与实践, 2010, 16(10): 954-957.

[5] Shaturny? V I, Shakhidzhanov SS, Sveshnikova AN, Panteleev MA. Activators, receptors and signal transduction pathways of blood platelets [J]. Biomed Khim. 2014, 60(2):182-200

[6] Liu Yang-yang, Hu Meng-jiao. Luo Dong-jiao, et al. Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase[J]. Arterioscler Thromb Vasc Biol, 2018, 38(3): e26-e27.

[7] Zoubir Djerada, Catherine Feliu, Vincent Richard. Current knowledge on the role of P2Y receptors in cardioprotection against ischemia-reperfusion [J]. Pharmacol Res, 2017, 118: 5-18.

[8] 陆四, 孟照辉. 血小板膜蛋白受体信号转导通路的研究进展[J]. 医学综述, 2014, 20(21): 3851-3854.

[9] Atkinson L, Yusuf1 M.Z, Aburima A, et al. Reversal of stress fibre formation by Nitric Oxide mediated RhoA inhibition leads to reduction in the height of preformed thrombi [J]. Sci Rep, 2018, 8(1):3032

[10] Yusuf M Z, Raslan Z, Atkinson L, et al. Prostacyclin reverses platelet stress fibre formation causing platelet aggregate instability [J]. Scientific, 2017, 7(1): 5582

[11] Wu Chin-chung, Teng Che-ming. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation [J]. Eur J Pharmacol, 2006, 546(1-3): 142-47.

[12] 余果宇，张勇，江萍. 蛋白酶激活受体[J]. 生命的化学, 2011, 31(03): 425-428.

[13] Beatrice Hechler, Christian Gachet. P2 receptors and platelet function［J］. Purinergic Signal, 2011, 7(3): 293-303

[14] Pia R M Siljander, Imke C A Munnix, Peter A Smethurst, et al. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood[J]. Blood, 2004, 103(4): 1333-1341.

[15] Jane F Arthur, Elizabeth Gardiner, Maria Matzaris, et al. Glycoprotein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets[J]. Thromb Haemost, 2005, 93(4): 716-23.

[16] 李雪晴, 耿婷. 血小板活化因子(PAF) 受体拮抗剂的研究进展[J].中国中药杂志, 2018, 24(04): 1392-1403

[17] Federico Iovino, Matthijs C Brouwer, Diederik van de Beek, et al. Signalling or binding: the role of the platelet-activating factor receptor in invasive pneumococcal disease [J]. Cell Microbiol, 2013, 15(6): 870-881

[18] Omair Yousuf, Deepak L Bhatt. The evolution of antiplatelet therapy in cardiovascular disease [J]. Nat Rev Cardiol, 2011, 8(10): 547-59.

[19] Gu X, Fu X, Wang Y, et al. Comparison of ticagrelor and high-dose clopidogrel on the platelet functions in patients with inadequate response to clopidogrel [J]. Am J Cardiovasc Dis, 2017, 7(1):1-8

[20] 董慧宇, 陈献华. P2Y12受体拮抗剂类抗血小板药物的研究新进展[J].中国新药杂志，2017, 26(12):1406-1411

[21] Beatrice Hechler, Christelle Nonne, Eun Joo Roh, et al. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice[J]. J Pharmacol Exp Ther, 2006, 316(2): 556-63.

[22] Maree A O, Cox D, Fitzgerald D J. Drug insight: aspirin resistance-fact or fashion? [J]. Nat Clin Pract Cardiovasc Med, 2007, 4(3): E1

[23] Xu Li-na, Yu Wen-gui, Tian Jin-ying, et al. Effect of sodium ferulate on arachidonic acid metabolism[J]. Acta Pharm Sin, 1990, 25(6) : 412-416.

[24] Jantan I, Raweh S M, Sirat H M, et al. Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation[J]. Phytomedicine, 2008, 15(4): 306-309

[25] Marilena Crescente, Gisela Jessen, Stefania Momi, et al. Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cycloox-ygenase-1 level. Functional and modelling studies[J]. Thromb Haemost, 2009, 102(2): 336-346.

[26] 张林山. PAR-1受体拮抗剂E5555类似物的研究[D]. 青岛: 青岛科技大学，2012.

[27] Shinya Goto, Testu Yamaguchi, Yasuo Ikeda, et al. Safety and exploratory efficacy of the novel thrombin receptor(PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome [J]. J Atheroscler. Thromb, 2010, 17 (2): 156-164.

[28] Jennifer Vergara-Jimenez, Pierluigi Tricoci. Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention [J]. Vasc Health Risk Manag, 2010, 6: 39-45.

[29] 陈俞宏, 李孝成. 低分子肝素结合替罗非班治疗老年急性下肢深静脉血栓对 PAC-1、P 选择素的影响[J]. 中国现代医学杂志, 2018, 28(03): 64-68

[30] 高稳, 李健. EＲK5对体外血小板活化及在体血栓的影响[J].中国病理生理杂志, 2017, 33(11): 1958-1963

[31] Li Wei, Yue Hong. Thymidine phosphorylase: A potential new target for treating cardiovascular disease [J]. Science Direc, 2018, 28(3): 157-171

[32] Diana A Gorog, Zahi A Fayad, Valentin Fuster. Arterial thrombus stability: does it matter and can we detect it? [J]. J Am Coll Cardiol, 2017, 70(16): 2036–2047.

[33] Diana A Gorog. Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [J]. J Thromb Thrombolysis, 2018, 45(4): 593-602.

相关文章 15

[1]	刘慧娟,白明,苗明三. 含天麻中成药的应用与分析[J]. 神经药理学报, 2019, 9(6): 26-30.
[2]	梁宇飞, 张欣欣, 赵丽艳, 等. 从姜黄素的代谢特点探讨姜黄素与胡椒碱的联合应用[J]. 神经药理学报, 2019, 9(6): 47-57.
[3]	宋宜蕾，侯雪芹，郝吉福. 蛇床子现代药理学作用及临床应用的研究进展[J]. 神经药理学报, 2019, 9(6): 58-63.
[4]	赵鹏慧，庞策，甄攀. 桑皮素治疗脑胶质瘤的新思路[J]. 神经药理学报, 2019, 9(5): 44-49.
[5]	杨琳，艾静. 脑源雌激素在阿尔茨海默病中的作用研究进展[J]. 神经药理学报, 2019, 9(5): 50-64.
[6]	苗明三，彭孟凡，方晓艳，贾佼佼，白明. 大血藤总酚酸对局灶性脑缺血再灌注大鼠脑组织氧化应激水平和能量代谢的影响[J]. 神经药理学报, 2019, 9(1): 1-5.
[7]	邸桐，赵智婕，包金风. 叶酸对母婴分离引起小鼠成年焦虑样行为影响的初探[J]. 神经药理学报, 2019, 9(1): 6-12.
[8]	吴县，洪浩. 胆汁酸及其受体与中枢神经系统疾病[J]. 神经药理学报, 2019, 9(1): 23-30.
[9]	魏珍珍，方晓艳，白明，苗明三. 基于星形胶质细胞的脑缺血损伤治疗研究进展[J]. 神经药理学报, 2019, 9(1): 36-43.
[10]	张丹参，苏晓梅. N- 甲基-D- 天冬氨酸受体在记忆网络中的作用[J]. 神经药理学报, 2019, 9(1): 44-62.
[11]	张帅，艾静. 谷氨酸功能异常与阿尔茨海默病[J]. 神经药理学报, 2018, 8(6): 9-20.
[12]	张海威，张丹参，苏晓梅，赵凯燕，武春阳，张力. 建立体外血脑脊液屏障模型方法学研究[J]. 神经药理学报, 2018, 8(3): 1-8.
[13]	刑媛，张楠,张炜，任雷鸣. 局麻药的中枢神经系统毒性与防治[J]. 神经药理学报, 2018, 8(3): 15-.
[14]	朱敏1,李凌海2. 麻醉药物应用与患者术后认知功能障碍的研究进展[J]. 神经药理学报, 2018, 8(3): 32-.
[15]	孙毅，谭博，苏瑞斌. 偏向性配体——阿片类镇痛药设计新思路[J]. 神经药理学报, 2018, 8(2): 1-7.

编辑推荐

Metrics

阅读次数

全文

摘要

摘要
参考文献
相关文章
编辑推荐
Metrics

回顶部